‌

US Patent 8840888 Dosage regimen for administering a CD19XCD3 bispecific antibody

Patent 8840888 was granted and assigned to Micromet on September, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Current Assignee

Micromet

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

8840888

Date of Patent

September 23, 2014

Patent Application Number

13504665

Date Filed

October 27, 2010

Patent Citations Received

‌

US Patent 11884733 Antibody variable domains targeting the NKG2D receptor

‌

US Patent 12129300 Antibody variable domains targeting the NKG2D receptor

‌

US Patent 11939384 Antibody variable domains targeting the NKG2D receptor

‌

US Patent 11834506 Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer

‌

US Patent 11884732 Proteins binding HER2, NKG2D and CD16

Patent Primary Examiner

‌

Sheela J. Huff

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8840888 Dosage regimen for administering a CD19XCD3 bispecific antibody

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API